More than 15 years’ experience in management of industrial R&D programs and in the discovery and development of novel small molecule therapeutics. Led the discovery and development of several drug candidates currently in preclinical and clinical stages. Dr. Huesca obtained degrees in Pharmaceutical Chemistry and Pharmacology from the University of Mexico (UNAM) and a PhD in Molecular Genetics and Microbiology from the University of Toronto.

Former co-founder of Select Therapeutics (successful NASDAQ exit); Sr. Scientist, the Hospital for Sick Children and Professor at the University of Toronto. PhD degree from the University of London, England. Published over 200 original scientific papers and numerous patents. Dr. Lingwood is a world leader in research on receptor function of glycosphingolipids, including their role in HIV attachment and fusion with human immune cells.